Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
Liver International : Official Journal of the International Association for the Study of the Liver|March 4, 2024
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinomaSatoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
Anticancer Research|August 5, 2010
Overexpression of MMP-13 gene in colorectal cancer with liver metastasisTakanobu Yamada, Takashi Oshima, Kazue Yoshihara, et al.
Anticancer Research|November 2, 2010
Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancerDaisuke Inagaki, Takashi Oshima, Kazue Yoshihara, et al.
European Journal of Gastroenterology & Hepatology|July 3, 2023
Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapyHaruki Uojima, Makoto Chuma, Hisashi Hidaka, et al.
BMC Cancer|May 7, 2022
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinomaSatoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
Journal of Hepatology|June 10, 2019
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysisThomas Yau, Chiun Hsu, Tae-You Kim, et al.
Liver Cancer|June 24, 2026
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup AnalysisMasatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, et al.
International Journal of Computer Assisted Radiology and Surgery|October 5, 2022
A VS ultrasound diagnostic system with kidney image evaluation functionsJiayi Zhou, Norihiro Koizumi, Yu Nishiyama, et al.
Journal of Gastroenterology|November 14, 2019
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subsetTatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENTKazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, et al.
Pageof 20